Investor access
We built an ecosystem designed to close its own financing window.
Early strategic capital accelerates the launch of new sites and the proof that follows. Once portfolio cash generation can fund the next brand on its own, we can stop issuing ownership instead of continuing to dilute the platform.
What LastStop is
One operating system, twenty category-specific telehealth sites.
LastStop separates what is protected from what is investable. The core IP and architecture sit in a private parent layer that is never offered. The operating company — DeploymentCo — raises capital and runs the portfolio.
Private parent / protected IP layer
Owns core IP, system architecture, future software, and trademarks. Not offered, and not included in DeploymentCo's valuation unless specific rights are licensed down.
DeploymentCo
Raises and operates the whole portfolio: centralized marketing, launch process, support, compliance workflow, and downstream brand relationships.
20-site portfolio + 10 in reserve
Each brand carries its own stage, partner, economics, capital requirement, and release decision. Ten additional brands stay in incubation.
Two ways in
Choose the whole engine, or a specific site.
Lane A — DeploymentCo minority equity
Primary capital at a $25M pre-money price, roughly 3.85% post-money if the full cap is subscribed.
- $100K → 0.40% post-money, $25.1M post
- $1.0M (full cap) → 3.85% post-money, $26.0M post
- Strategic participation in the whole downstream operating engine — every current and future site
- No rights in the protected parent / IP layer
Lane B — Site or bundle participation
Site-level or bundle-level economics, priced by cohort. No DeploymentCo equity, no parent/IP rights.
- Founding cohort (Sites 1-2): $50K media commitment
- Early / Proof / Scale cohorts: $50K media + $25K-$150K launch
- De-risked cohort (Sites 6-20): $50K media + $250K+ launch
- Or a multi-site bundle SPV across a category (e.g. metabolic, longevity, men's or women's health)
What you can touch, and what you cannot
The line is drawn on purpose.
Available to investors
- DeploymentCo minority equity (Lane A)
- Specific site or multi-site bundle economics (Lane B)
- Portfolio and site-level reporting
- Cohort pricing, dilution math, and the valuation proof — all shown, not asserted
Never offered
- Core IP or system architecture
- Trademarks or strategic rights held by the parent layer
- The future HealthOS software platform
- Automatic upgrade between lanes — a site investor doesn't become a DeploymentCo holder, and a DeploymentCo holder doesn't get preferential brand-level economics
Scarcity is policy, not a countdown
Inventory status reflects an allocation decision, not a marketing timer.
Of the 20 sites in the current portfolio: 6 are available, 1 is reserved for diligence, and 13 are currently retained by management.
Management can withdraw unopened inventory, decline applicants, or reprice future allocations — but accepted terms are never changed retroactively. After the first five or six placements, management can stop releasing sites entirely if internal cash generation is the better option.
The valuation, honestly
The $25M pre-money price is a target, not a claim we're hiding.
At the model's default assumptions — $3M annualized net revenue, $1M true recurring ARR, $500K EBITDA — the strongest of three standard methods (2.7x net revenue) supports about $8.1M. That leaves a real gap to close.
The bridge is not a narrative, it's a sequence: three live sites, then five, then six months of cohort data, then at least two acquisition channels, then $3M+ in annualized net revenue, then $2M+ EBITDA or $3M+ high-quality recurring ARR. At that point $25M is a multiple, not a personality test. We'd rather show the gap than pretend it isn't there — investors who run the numbers respect that more than a number with no method behind it.
25 revenue lines without more equity
The portfolio is built to monetize more than the media spend.
- 01 Launch / integration fee
- 02 Platform / operating license
- 03 Media buying management
- 05 ClaimRight compliance service
- 06 Provider operations support
- 07 Pharmacy routing / admin services
- 15 White-label platform licensing
- 25 Future HealthOS software licensing outside DeploymentCo
Redundancy and compliance
No single vendor is a single point of failure.
Provider and pharmacy layer
We're in active conversations with national provider networks — including OpenLoop and Wheel — alongside pharmacy fulfillment partners, so no one relationship can stall the portfolio. These are prospective conversations, not signed contracts, and we say so plainly.
ClaimRight compliance layer
Claim review, policy configuration, and consent/audit setup run through a dedicated compliance workflow before a site goes live, and stay in place as it scales.
How it works
From first look to a funded, reporting site.
Discover
Review the ecosystem, current inventory, and the two capital lanes.
Review the economics
Run the dilution calculator and the valuation-proof math yourself in the Allocation Room.
Apply
Tell us which lane, which sites or bundle, and why it's a strategic fit.
Diligence
Approved applicants get data-room access under NDA — term sheets and gated materials live there, not on the public site.
Verify and subscribe
Accreditation verification, subscription, and funding follow the offering's exemption pathway.
Launch and report
Funded sites go live against a launch checklist; every cohort's results feed the next round's pricing.
Ready to see the numbers